Lightpoint Medical develops molecular imaging and sensing technologies to help surgeons detect cancer in real time during surgery. In spite of the technological advances in robotic surgery, surgeons still depend on their eyesight to detect cancer intra-operatively. As a result, surgeons sometimes leave cancer behind or remove more healthy tissue than needed.
The company’s award-winning SENSEI® technology, a miniaturised intra-operative cancer detection probe, gives surgeons a chance to fully remove cancer in one procedure, while retaining healthy tissue. It can be used across many major cancer types including stomach, colorectal, breast, prostate, and lung cancer.
Dr Kunal Vyas is the Head of Research at Lightpoint Medical, responsible for evaluating new technologies, overseeing research projects and developing the company’s intellectual property (IP) portfolio. Kunal joined the SME Leaders programme in 2021. He says “I hope that the programme’s strategic innovation management initiative will maximise my performance as we commercialise and scale-up. I will also benefit from access to workshops and speaker events on topics such as IP management and pitching.”
In 2021, SENSEI® received CE mark, enabling it to be sold in the European Economic Area. Lightpoint Medical has begun multi-centre clinical trials with the probe. The company will now transition from being an R&D-focused organisation into a commercial enterprise.